Influence of age on the pharmacokinetics of i.v. vinflunine: Results of a phase I trial in elderly cancer patients

Urothelial carcinoma management in elderly or unfit patients

“…In addition, vinflunine is safe in elderly patients; most common AEs do not differ from those seen in younger patients. Similarly to patients with renal impairment, based on pharmacokinetic and safety data, vinflunine should be started at 280 mg/m 2 q3w in patients who are aged 75–79 years, and the dose should be lowered to 250 mg/m 2 q3w in patients aged ≥80 years who are in good shape [107] . The decision on which dose to administer depends on biological parameters.…”

Trends in cancer of the urinary bladder and urinary tract in elderly in Denmark, 2008–2012

“…It has been suggested, however, that the proportion of RT BC patients with co-morbidity decreases with age [21]. Other treatment options, including hyperfractionation and concomitant radiosensitizing chemotherapy, have been suggested also for the elderly population, and seem to be feasible, but it is unknown if these treatments result in better tolerability or clinical outcome [22]. RT is a recommended treatment for patients with localized BC who are ineligible for cystectomy, including the elderly [23].…”

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report

“…Principal VFL-related side effects include: constipation, anemia, neutropenia, vomiting and stomatitis. However, VFL has been proved to be acceptable also for elderly patients if dose reduction and granulocyte-colony stimulating factors (G-CSF) prophylaxis are observed [ 7 ]. With this evidence, the activity of a VFL based doublet as first-line therapy has been successfully explored in a phase II trial conducted in patients un-fit for cisplatin and a phase III trial comparing VFL-gemcitabine versus carboplatin-gemcitabine in the same setting is ongoing [ 8 ].…”